Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial
I'm PortAI, I can summarize articles.
Akeso Inc. announced a significant label update for its bispecific antibody, ivonescimab, after approval by China's National Medical Products Administration. The update is based on the HARMONi-A Phase III trial, showing significant improvements in progression-free survival (PFS) and overall survival (OS) for patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC) post-EGFR-TKI therapy. The final analysis indicated a 26% reduction in death risk and a 54% reduction in disease progression risk compared to chemotherapy alone. Ivonescimab is now included in China's National Reimbursement Drug List for specific NSCLC indications.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments